Análisis de la acción Valneva SE (VALN)VALNValneva SE

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products. It operates in the Healthcare sector.

Valneva SE is currently a hold. The stock is trading at $6.43, which is below the Fibonacci Pivot level of $6.836, indicating potential resistance. The RSI is at 43.474, suggesting it is neither overbought nor oversold, which means there could be further downside risk. Additionally, the forward P/E is extremely high at 666.67, indicating that the stock may be overvalued based on future earnings expectations. However, the recent acceptance of the Lyme disease vaccine application by the European Medicines Agency could provide a significant upside if approved, with analysts predicting a potential price target of $12. The main risk is the significant net loss of €63.3 million reported in H1 2026, which reflects ongoing financial challenges.